Cyclo Inventory vs Non Currrent Assets Other Analysis
| CYTH Stock | USD 0.73 0.03 4.29% |
Cyclo Therapeutics financial indicator trend analysis is way more than just evaluating Cyclo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cyclo Therapeutics is a good investment. Please check the relationship between Cyclo Therapeutics Inventory and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.
Inventory vs Non Currrent Assets Other
Inventory vs Non Currrent Assets Other Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cyclo Therapeutics Inventory account and Non Currrent Assets Other. At this time, the significance of the direction appears to have no relationship.
The correlation between Cyclo Therapeutics' Inventory and Non Currrent Assets Other is 0.02. Overlapping area represents the amount of variation of Inventory that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Cyclo Therapeutics, assuming nothing else is changed. The correlation between historical values of Cyclo Therapeutics' Inventory and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Inventory of Cyclo Therapeutics are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Inventory i.e., Cyclo Therapeutics' Inventory and Non Currrent Assets Other go up and down completely randomly.
Correlation Coefficient | 0.02 |
| Relationship Direction | Positive |
| Relationship Strength | Insignificant |
Inventory
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most indicators from Cyclo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Issuance Of Capital Stock is increasing as compared to previous years. The Cyclo Therapeutics' current Sales General And Administrative To Revenue is estimated to increase to 5.52, while Selling General Administrative is projected to decrease to under 2.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 15.7M | 16.8M | 17.6M | 18.5M | Cost Of Revenue | 156.1K | 138.9K | 3.5M | 3.7M |
Cyclo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cyclo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cyclo Therapeutics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.1M | 14.2M | 19.5M | 4.2M | 13.2M | 13.9M | |
| Total Current Liabilities | 3.1M | 3.7M | 3.8M | 3.5M | 8.5M | 8.9M | |
| Total Stockholder Equity | 936.0K | 10.5M | 15.7M | 734.5K | 4.8M | 2.6M | |
| Property Plant And Equipment Net | 64.6K | 87.9K | 77.2K | 56.7K | 929.3K | 505.7K | |
| Net Debt | (2.7M) | (12.7M) | (16.4M) | (1.5M) | (8.2M) | (7.8M) | |
| Retained Earnings | (25.1M) | (34.1M) | (48.3M) | (63.8M) | (83.9M) | (79.7M) | |
| Accounts Payable | 3.1M | 3.5M | 3.7M | 2.2M | 4.9M | 5.1M | |
| Cash | 2.8M | 12.8M | 16.6M | 1.5M | 9.2M | 9.7M | |
| Non Current Assets Total | 155.2K | 137.7K | 84.5K | 56.7K | 929.3K | 694.6K | |
| Non Currrent Assets Other | 90.6K | 49.8K | 7.3K | (56.7K) | 38.3K | 36.4K | |
| Cash And Short Term Investments | 2.8M | 12.8M | 16.6M | 1.5M | 9.2M | 9.7M | |
| Net Receivables | 182.5K | 111.8K | 539.1K | 55.0K | 122.4K | 105.2K | |
| Common Stock Shares Outstanding | 1.1M | 1.6M | 6.4M | 8.4M | 16.3M | 17.1M | |
| Liabilities And Stockholders Equity | 4.1M | 14.2M | 19.5M | 4.2M | 13.2M | 13.9M | |
| Non Current Liabilities Total | 36.1K | 62.9K | 18.0K | 3.5M | 22.5K | 21.4K | |
| Inventory | 242.6K | 237.9K | 227.4K | 254.5K | 254.4K | 250.7K | |
| Other Current Assets | 749.2K | 854.4K | 2.1M | 4.6M | 2.7M | 2.8M | |
| Other Stockholder Equity | 26.0M | 44.5M | 64.0M | 64.5M | 88.6M | 93.0M | |
| Total Liab | 3.2M | 3.7M | 3.8M | 3.5M | 8.5M | 8.9M | |
| Total Current Assets | 4.0M | 14.1M | 19.4M | 4.2M | 12.3M | 12.9M | |
| Common Stock | 12.2K | 477.0 | 841.0 | 849.0 | 2.9K | 3.7K | |
| Net Tangible Assets | 936.0K | 10.5M | 15.7M | 734.5K | 844.7K | 802.5K | |
| Other Assets | 129.7K | 90.6K | 49.8K | 7.3K | 6.6K | 6.2K | |
| Property Plant Equipment | 64.6K | 87.9K | 77.2K | 56.7K | 65.2K | 56.7K | |
| Net Invested Capital | 936.0K | 10.6M | 15.8M | 734.5K | 4.8M | 5.5M | |
| Property Plant And Equipment Gross | 64.6K | 87.9K | 159.3K | 158.2K | 1.1M | 1.1M | |
| Net Working Capital | 816.9K | 10.4M | 15.6M | 677.9K | 3.9M | 5.2M | |
| Capital Stock | 12.2K | 477.0 | 841.0 | 849.0 | 2.9K | 3.5K |
Currently Active Assets on Macroaxis
When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.90) | Revenue Per Share 0.046 | Quarterly Revenue Growth 0.051 | Return On Assets (2.82) | Return On Equity (226.64) |
The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.